Drugs.com Clinical Trial ResultsOriginal article
BioNTech Provides Update on Phase 2 Clinical Trial of Autogene Cevumeran in Resected Colorectal Cancer
Phase 2negativeautogene cevumeranNegative
AI Analysis
Summary
BioNTech announced termination of the Phase 2 clinical trial (BNT122-01) evaluating autogene cevumeran in patients with resected colorectal cancer. The decision to discontinue the trial represents a negative clinical development for the candidate asset.
Clinical Trial Data
Outcome Details
Phase 2 clinical trial terminated
Importance:7/10
Sentiment:
-0.80
trial terminationoncologycolorectal cancerBNT122
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 28, 2026 1:09 AM